- Home
- MTN vs MDGL Comparison
MTN vs MDGL Comparison
Compare MTN & MDGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MTN
- MDGL
- Stock Information
- Founded
- MTN 1997
- MDGL 2011
- Country
- MTN United States
- MDGL United States
- Employees
- MTN N/A
- MDGL N/A
- Industry
- MTN Services-Misc. Amusement & Recreation
- MDGL Biotechnology: Pharmaceutical Preparations
- Sector
- MTN Consumer Discretionary
- MDGL Health Care
- Exchange
- MTN Nasdaq
- MDGL Nasdaq
- Market Cap
- MTN 6.1B
- MDGL 6.1B
- IPO Year
- MTN 1997
- MDGL N/A
- Fundamental
- Price
- MTN $148.52
- MDGL $315.33
- Analyst Decision
- MTN Hold
- MDGL Strong Buy
- Analyst Count
- MTN 10
- MDGL 9
- Target Price
- MTN $186.50
- MDGL $420.63
- AVG Volume (30 Days)
- MTN 629.5K
- MDGL 371.3K
- Earning Date
- MTN 09-25-2025
- MDGL 08-05-2025
- Dividend Yield
- MTN 5.96%
- MDGL N/A
- EPS Growth
- MTN 6.60
- MDGL N/A
- EPS
- MTN 7.74
- MDGL N/A
- Revenue
- MTN $2,958,444,000.00
- MDGL $317,383,000.00
- Revenue This Year
- MTN $3.74
- MDGL $286.67
- Revenue Next Year
- MTN $3.78
- MDGL $67.98
- P/E Ratio
- MTN $19.24
- MDGL N/A
- Revenue Growth
- MTN 2.38
- MDGL N/A
- 52 Week Low
- MTN $129.85
- MDGL $200.63
- 52 Week High
- MTN $199.45
- MDGL $377.46
- Technical
- Relative Strength Index (RSI)
- MTN 35.74
- MDGL 50.42
- Support Level
- MTN $157.01
- MDGL $286.44
- Resistance Level
- MTN $161.82
- MDGL $312.05
- Average True Range (ATR)
- MTN 3.55
- MDGL 14.41
- MACD
- MTN -1.66
- MDGL -2.44
- Stochastic Oscillator
- MTN 8.78
- MDGL 25.86
About MTN Vail Resorts Inc.
Vail Resorts Inc Bhd is a resorts and casinos company that operates mountain resorts and ski areas. The company has three business segments that include Mountain, Lodging, and Real Estate. The Mountain segment operates numerous ski resort properties that offer a variety of winter and summer activities, such as skiing, snowboarding, snowshoeing, hiking, and mountain biking. The Lodging segment owns and operates hotels and condominiums. The Real Estate segment owns, develops, and leases real estate, typically near its other properties. The company generates the vast majority of its revenue within the United States.
About MDGL Madrigal Pharmaceuticals Inc.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.